Curcumin-based Neurokinin 3 Receptor Modulation for Animal Health

Publication ID: 24-11857594_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Curcumin-based Neurokinin 3 Receptor Modulation for Animal Health,” Published Technical Disclosure No. 24-11857594_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857594_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,594.

Summary of the Inventive Concept

This inventive concept leverages the core technology of curcumin compositions as neurokinin 3 (NK3) antagonists to develop novel applications in animal health, addressing unmet needs in companion animals, agricultural livestock, aquaculture, and poultry.

Background and Problem Solved

The original patent disclosed curcumin compositions as NK3 antagonists for human therapeutic applications. However, the limitations of this technology were restricted to human use cases, leaving a significant gap in addressing similar health issues in animals. This inventive concept solves this problem by exploring new applications and use cases for curcumin-based NK3 receptor modulation in animal health.

Detailed Description of the Inventive Concept

The inventive concept involves the development of curcumin compositions specifically formulated to cross the blood-brain barrier and inhibit NK3 receptor activity in various animal species. This is achieved through the creation of novel formulations, such as veterinary formulations, feed supplements, and aquaculture compositions, which selectively target NK3 receptors in the central nervous system of animals. The new claims encompass a range of applications, including treating neurodegenerative disorders in companion animals, reducing anxiety in agricultural livestock, and improving growth rates in poultry.

Novelty and Inventive Step

The new claims introduce a novel and non-obvious application of curcumin-based NK3 receptor modulation in animal health, distinct from the original patent's focus on human therapeutic applications. The inventive concept's novelty lies in its tailored formulations and targeted delivery mechanisms, which enable effective modulation of NK3 receptors in various animal species.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the development of transdermal patches, injectable formulations, or oral tablets for animal use. Variations could also involve combining curcumin with other natural compounds or pharmacological agents to enhance its efficacy and bioavailability.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the animal health industry, with potential applications in veterinary medicine, agricultural production, and aquaculture. The target market includes animal health companies, veterinarians, farmers, and aquaculture operators seeking innovative solutions to improve animal welfare and productivity.

CPC Classifications

SectionClassGroup
A A61 A61K36/9066
A A61 A61K31/26
A A61 A61K36/82
A A61 A61P15/12

Original Patent Information

Patent NumberUS 11,857,594
TitleCurcumin compositions and methods of use as an NK3 antagonist
Assignee(s)JDS Therapeutics, LLC